行情

ARCT

ARCT

Arcturus
NASDAQ

实时行情|Nasdaq Last Sale

9.55
-0.15
-1.50%
交易中 14:31 11/19 EST
开盘
9.69
昨收
9.69
最高
9.91
最低
9.27
成交量
6.01万
成交额
--
52周最高
15.50
52周最低
4.110
市值
1.02亿
市盈率(TTM)
-6.7451
分时
5日
1月
3月
1年
5年

分析师评级

7位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

ARCT 新闻

  • Rock star Growth Puts Arcturus Therapeutics Holdings (NASDAQ:ARCT) In A Position To Use Debt
  • Simply Wall St..11/11 11:56
  • Arcturus Therapeutics EPS misses by $0.09, misses on revenue
  • seekingalpha.11/08 02:55
  • Arcturus Therapeutics Announces Third Quarter Financial Results and Provides Corporate Update
  • GlobeNewswire.11/07 21:01
  • Arcturus Therapeutics Expands Platform with STARR Technology
  • GlobeNewswire.11/07 12:30

更多

所属板块

生物技术和医学研究
+2.18%
制药与医学研究
+0.76%

热门股票

名称
价格
涨跌幅

ARCT 简况

Arcturus Therapeutics Ltd. is a ribonucleic acid (RNA) medicines company. The Company owns Lipid-enabled and Unlocked Nucleomonomer Agent modified RNA (LUNAR) lipid-mediated delivery and Unlocked Nucleomonomer Agent (UNA) technology, including UNA Oligomers. The Company’s diverse pipeline of RNA therapeutics includes programs pursuing rare diseases, Hepatitis B, non-alcoholic steatohepatitis (NASH), cystic fibrosis and vaccines. The Company’s versatile RNA therapeutics platforms can be applied toward multiple types of RNA medicines, including small interfering RNA, messenger RNA, replicon RNA, antisense RNA, microRNA and gene editing therapeutics. The Company's UNA technology can be used to target individual genes in the human genome, as well as viral genes, and other species for therapeutic purposes.
展开

Webull提供Arcturus Therapeutics Ltd的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。